Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Alibaba, Abbott Laboratories, T-Mobile, Anheuser-Busch and Boston Scientific Corp

Read MoreHide Full Article

For Immediate Release

Chicago, IL – November 11, 2021 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alibaba Group Holding Limited (BABA - Free Report) , Abbott Laboratories (ABT - Free Report) , T-Mobile US, Inc. (TMUS - Free Report) , Anheuser-Busch InBev SA/NV (BUD - Free Report) and Boston Scientific Corporation (BSX - Free Report) .

Here are highlights from Wednesday’s Analyst Blog:

Top Analyst Reports for Alibaba, Abbott and T-Mobile

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alibaba, Abbott Laboratories, and T-Mobile. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Alibaba have underperformed the S&P 500 in the past three months (-17.7% vs. +5.8%). The company is susceptible to certain risks due to the strict laws in China, which along with lower mobile monetization, increasing competition and integration risks have been weighing on its revenues.

The Zacks analyst, however, believes that its dominance in the mobile commerce market, continued efforts to develop new products, international growth opportunities and strong financial position are some of the near-term tailwinds. The company’s strengthening cloud business on the back of its expanding customer base also continues to drive its performance.

(You can read the full research report on Alibaba here >>>)

Abbott shares have gained +17.3% in the year to date period against the Zacks Medical Products industry’s gain of +2.8%. The Zacks analyst believes that the company’s branded generics and international diabetes businesses are likely to drive growth in the quarters ahead.

Abbott reported better-than-expected earnings for the third quarter of 2021. Barring Neuromodulation, the company registered organic sales growth across each of its operating segments. Diabetes Care sales, in the quarter, also benefited from the solid worldwide adoption of FreeStyle Libre. A challenging business environment and slow growth in the nutrition business in China are some of the major headwinds though.

(You can read the full research report on Abbott here >>>)

Shares of T-Mobile US have lost -4.2% over the past year against the Zacks National Wireless industry’s loss of -7.4%. The company is, however, expanding its 5G network to bring fast and affordable wireless service across the country. The Zacks analyst believes that such developments would unlock massive synergies for it.

It has expanded its Home Internet service to 51 cities across Florida, Georgia, North Carolina, and South Carolina. T-Mobile’s Extended Range 5G covers 308 million people across 1.7 million square miles. The company, however, operates in a fiercely competitive and an almost saturated U.S. telecom market which has been weighing on its revenues.

(You can read the full research report on T-Mobile US here >>>)

Other noteworthy reports we are featuring today include Anheuser-Busch and Boston Scientific Corp.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.